ScholarIQanswers from OpenAlex
Neuroblastoma Research and Treatments
TopicLeading institutions, researchers & key papers
Neuroblastoma Research and Treatments is a topic indexed in ScholarIQ from OpenAlex.
What is known about Neuroblastoma Research and Treatments?
ScholarIQrecord summary
This cluster of papers represents a comprehensive exploration of neuroblastoma, covering topics such as genetic mutations (including ALK and MYCN), risk classification, staging systems, immunotherapy, and genomic analysis. The research also delves into therapy strategies and prognosis for patients with neuroblastoma.
How many works does Neuroblastoma Research and Treatments have?
ScholarIQindexed works
Neuroblastoma Research and Treatments has 282 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Neuroblastoma Research and Treatments?
ScholarIQopenalex
The OpenAlex for Neuroblastoma Research and Treatments is on the source record.
What are the most-cited papers on Neuroblastoma Research and Treatments?
ScholarIQmost cited works
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Véronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel, Katherine K. Matthay
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix‐Lerosey, Delphine Lequin, Laurence Brugières, Agnès Ribeiro, Loïc de Pontual, Valérie Combaret, Virginie Raynal, Alain Puisieux, Gudrun Schleiermacher, Gaëlle Pierron, Dominique Valteau‐Couanet, Thierry Frébourg, Jean Michon, Stanislas Lyonnet, Jeanne Amiel, Olivier Delattre
Synapse formation between central neurons requires postsynaptic expression of the MEN1 tumor suppressor gene.
Ronald E. van Kesteren, Naweed I. Syed, David W. Munno, Jildau Bouwman, Zhong‐Ping Feng, Wijnand P. M. Geraerts, August B. Smit
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
Wenqian Zhang, Ying Yu, Falk Hertwig, Jean Thierry‐Mieg, Wenwei Zhang, Danielle Thierry‐Mieg, Jian Wang, Cesare Furlanello, Viswanath Devanarayan, Jie Cheng, Youping Deng, Barbara Hero, Huixiao Hong, Meiwen Jia, Li Li, Simon Lin, Yuri Nikolsky, André Oberthuer, Tao Qing, Zhenqiang Su, Ruth Volland, Charles Wang, May D. Wang, Junmei Ai, Davide Albanese, Shahab Asgharzadeh, Smadar Avigad, Wenjun Bao, Marina Bessarabova, Murray H. Brilliant, Benedikt Brors, Marco Chierici, Tzu‐Ming Chu, Jibin Zhang, Richard G. Grundy, Min He, Scott J. Hebbring, Howard L. Kaufman, Samir Lababidi, Lee Lancashire, Yan Li, Xin X. Lu, Heng Luo, Xiwen Ma, Baitang Ning, Rosa Noguera, Martin Peifer, John H. Phan, Frederik Roels, Carolina Rosswog, Susan Shao, Jie Shen, Jessica Theißen, Gian Paolo Tonini, Jo Vandesompele, Po-Yen Wu, Wenzhong Xiao, Joshua Xu, Weihong Xu, Jiekun Xuan, Yong Yang, Zhan Ye, Zirui Dong, Ke Zhang, Ye Yin, Chen Zhao, Yuanting Zheng, Russell D. Wolfinger, Tieliu Shi, Linda H. Malkas, Frank Berthold, Jun Wang, Weida Tong, Leming Shi, Zhiyu Peng, Matthias Fischer
Molecular targeting therapies for neuroblastoma: Progress and challenges
Atif Zafar, Wei Wang, Gang Liu, Xinjie Wang, Wa Xian, Frank McKeon, Jennifer H. Foster, Jia Zhou, Ruiwen Zhang
Where is Neuroblastoma Research and Treatments research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Neuroblastoma Research and Treatments is open access?
ScholarIQopen access share
53%OPEN ACCESS